Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Partners offer FUT8 knockout CHO DG44 cell line services
August 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

MORGAN HILL, Calif.—Aragen Bioscience Inc. and Transposagen Biopharmaceuticals Inc. have developed a FUT8 knockout CHO DG44 host cell line, with Aragen to offer protein expression and cell line development services with this cell line for products to be used for research purposes. The launch of this cell line is expected in the second half of 2015. Transposagen is offering custom gene-editing services using the FUT8 knockout CHO DG44 host cell line, and will also offer gene-editing kits with the cell line and its unique technologies, including Footprint-Free Gene Editing, to create disease-specific cell lines and XTNTM TALEN or NextGEN CRISPRs to create additional gene knockouts and knock-ins. Dr. Oren Beske, chief operating officer of Aragen, said “Easy access to this unique service further broadens our portfolio and positions Aragen Bioscience as a value-added partner to the biopharmaceutical industry.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.